Answer First
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in a human gastric protein. TB-500 is a synthetic peptide fragment based on Thymosin Beta-4, a 43-amino-acid protein. The two have different molecular origins and distinct mechanism categories in the research literature — BPC-157 research concentrates on gastric and musculoskeletal tissue models, TB-500 research concentrates on cardiac and soft-tissue models — and researchers frequently study them together for potentially complementary effects.
Molecular identity
Despite both being grouped under "tissue repair peptides," BPC-157 and TB-500 are structurally unrelated. Understanding their distinct origin is the starting point for designing any comparative or combination protocol.
| Property | BPC-157 | TB-500 |
|---|---|---|
| Sequence length | 15 amino acids (pentadecapeptide) | Fragment of a 43-amino-acid parent protein |
| Approximate molecular weight | ~1,419 g/mol | ~889 g/mol (common 4-17 fragment) to ~4,963 g/mol (full Thymosin Beta-4) |
| Molecular origin | Synthetic fragment derived from human gastric juice protein BPC | Synthetic fragment derived from Thymosin Beta-4, a naturally occurring actin-regulating protein |
| Structural class | Short synthetic peptide | Actin-binding protein fragment |
| Year first characterized | Late 1990s (Croatian research group) | Thymosin Beta-4 characterized in the 1960s-70s; TB-500 fragment developed later |
Because BPC-157 is a short, stable synthetic sequence and TB-500 is a fragment of a naturally occurring actin-regulatory protein, they are studied through different experimental lenses even when the research question (tissue repair) overlaps.
Research literature focus areas
Published research on each compound tends to cluster in different physiological systems, though there is some overlap.
- BPC-157 literature concentrates on gastric mucosa protection, gastrointestinal models, and musculoskeletal tissue models including tendon, ligament, and muscle injury in animal studies. Its origin in gastric protein research shapes much of the early literature.
- TB-500 (Thymosin Beta-4) literature concentrates on cardiac tissue models, wound healing, angiogenesis (new blood vessel formation), and cell migration mechanisms tied to its role in actin regulation within cells.
Both bodies of literature are predominantly preclinical — conducted in cell culture and animal models. Neither compound has FDA approval for any human therapeutic indication, and both are supplied strictly for research use.
Administration in research protocols
Both peptides are typically prepared and handled the same way in laboratory settings, though study designs vary in concentration and frequency depending on the model system.
Standard handling protocol (applies to both)
- Reconstitute with bacteriostatic water, added slowly along the vial wall rather than directly onto the lyophilized powder.
- Swirl gently, do not shake, until fully dissolved.
- Refrigerate at 2–8°C immediately after reconstitution.
- Use within the documented stability window referenced on the batch COA.
- Record reconstitution date and concentration on the vial for protocol traceability.
- Store lyophilized (unreconstituted) vials frozen or refrigerated until ready for use to maximize shelf stability.
Can they be used together in research protocols?
Because BPC-157 and TB-500 are studied through different mechanism categories — one centered on gastric/musculoskeletal pathways, the other on cardiac/angiogenic and cell-migration pathways — some published and community-reported research protocols pair the two compounds to examine potentially complementary effects on tissue repair models. Combination protocols are typically designed with each compound reconstituted and stored separately, then administered according to independent dosing schedules within the same study window. As with any multi-compound protocol, researchers should document each compound's batch number and reconstitution parameters independently to preserve traceability.
Side-by-side summary
| Factor | BPC-157 | TB-500 |
|---|---|---|
| Structural class | Synthetic pentadecapeptide | Synthetic Thymosin Beta-4 fragment |
| Primary literature focus | Gastric & musculoskeletal models | Cardiac & soft-tissue models |
| Reconstitution | Bacteriostatic water, refrigerate | Bacteriostatic water, refrigerate |
| Human clinical data | Limited | Limited |
| Often studied in combination | Yes | Yes |
| Available at Sequence Labs | Yes — product page | Yes — product page |
Frequently asked questions
What's the sequence difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric protein sequence. TB-500 is a synthetic fragment representing the active region of Thymosin Beta-4, a 43-amino-acid actin-regulating protein. The two are structurally unrelated despite both being classified as tissue-repair research peptides.
Which has more human data?
Neither has an extensive body of controlled human clinical trial data. Most published research on both compounds is preclinical, conducted in cell culture and animal models. Both remain research compounds without FDA-approved human therapeutic indications.
How do you reconstitute them?
Both are supplied lyophilized and reconstituted with bacteriostatic water added slowly along the vial wall, then gently swirled — never shaken — until fully dissolved, followed by immediate refrigeration.
How stable are they after reconstitution?
Both are commonly reported as stable for several weeks under refrigeration when protected from light and temperature fluctuation. Unreconstituted lyophilized powder is stable substantially longer when kept frozen or refrigerated.
What purity should I look for?
A third-party Certificate of Analysis showing HPLC purity of 98% or higher, mass spectrometry confirming the expected molecular weight, and a traceable batch number matching the vial label.